Medical and surgical management of obesity and diabetes: what's new?
Corresponding Author
B. J. Ammori
Department of Surgery, King Hussein Cancer Centre, Amman, Jordan
Correspondence to: Basil J. Ammori. E-mail: [email protected]
Search for more papers by this authorM. C. Skarulis
National Obesity Treatment Centre, Hamad Medical Corporation, Doha, Qatar
Search for more papers by this authorH. Soran
Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK
Department of Medicine, Manchester University NHS Foundation Trust, Manchester, UK
Search for more papers by this authorA. A. Syed
Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK
Department of Diabetes and Endocrinology, Salford Royal NHS Foundation Trust, Salford, UK
Search for more papers by this authorM. Eledrisi
Department of Diabetes and Endocrinology, Hamad Medical Corporation, Doha, Qatar
Department of Medicine, Weill Cornell Medicine-Qatar, Doha, Qatar
Search for more papers by this authorR. A. Malik
Department of Diabetes and Endocrinology, Hamad Medical Corporation, Doha, Qatar
Department of Medicine, Weill Cornell Medicine-Qatar, Doha, Qatar
Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK
Search for more papers by this authorCorresponding Author
B. J. Ammori
Department of Surgery, King Hussein Cancer Centre, Amman, Jordan
Correspondence to: Basil J. Ammori. E-mail: [email protected]
Search for more papers by this authorM. C. Skarulis
National Obesity Treatment Centre, Hamad Medical Corporation, Doha, Qatar
Search for more papers by this authorH. Soran
Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK
Department of Medicine, Manchester University NHS Foundation Trust, Manchester, UK
Search for more papers by this authorA. A. Syed
Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK
Department of Diabetes and Endocrinology, Salford Royal NHS Foundation Trust, Salford, UK
Search for more papers by this authorM. Eledrisi
Department of Diabetes and Endocrinology, Hamad Medical Corporation, Doha, Qatar
Department of Medicine, Weill Cornell Medicine-Qatar, Doha, Qatar
Search for more papers by this authorR. A. Malik
Department of Diabetes and Endocrinology, Hamad Medical Corporation, Doha, Qatar
Department of Medicine, Weill Cornell Medicine-Qatar, Doha, Qatar
Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK
Search for more papers by this authorAbstract
We conducted a narrative review of the medical and surgical management of people with obesity and diabetes. Results of this review showed that a 5–10% loss in body weight can be achieved with a change in lifestyle, diet and behaviour and with approved pharmacological therapies in people with obesity and diabetes. New targeted therapies are now available for patients with previously untreatable genetic causes of obesity. Compared to medical treatment, metabolic and bariatric surgery is associated with significantly higher rates of remission from type 2 diabetes and lower rates of incident macrovascular and microvascular complications and mortality. The National Institute for Health and Care Excellence and the American Diabetes Association endorse metabolic and bariatric surgery in obese adults with type 2 diabetes and there may also be a role for this in obese individuals with type 1 diabetes. The paediatric committee of the American Society for Metabolic and Bariatric Surgery have recommended metabolic and bariatric surgery in obese adolescents with type 2 diabetes. Earlier and more aggressive treatment with metabolic and bariatric surgery in obese or overweight people with diabetes can improve morbidity and mortality.
References
- 1Allison DB, Downey M, Atkinson RL, Billington CJ, Bray GA, Eckel RH et al. Obesity as a disease: a white paper on evidence and arguments commissioned by the Council of the Obesity Society. Obesity (Silver Spring, Md) 2008; 16: 1161–1177.
- 2Pilitsi E, Farr OM, Polyzos SA, Perakakis N, Nolen-Doerr E, Papathanasiou AE et al. Pharmacotherapy of obesity: Available medications and drugs under investigation. Metabolism 2019; 92: 170–192.
- 3Andermann ML, Lowell BB. Toward a Wiring Diagram Understanding of Appetite Control. Neuron 2017; 95: 757–778.
- 4Gerstein HC, Santaguida P, Raina P, Morrison KM, Balion C, Hunt D et al. Annual incidence and relative risk of diabetes in people with various categories of dysglycemia: a systematic overview and meta-analysis of prospective studies. Diabetes Res Clin Pract 2007; 78: 305–312.
- 5Haw JS, Galaviz KI, Straus AN, Kowalski AJ, Magee MJ, Weber MB et al. Long-term Sustainability of Diabetes Prevention Approaches: A Systematic Review and Meta-analysis of Randomized Clinical Trials. JAMA Intern Med 2017; 177: 1808–1817.
- 6Lean ME, Leslie WS, Barnes AC, Brosnahan N, Thom G, McCombie L et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet 2018; 391: 541–551.
- 7Hallberg SJ, Gershuni VM, Hazbun TL, Athinarayanan SJ. Reversing Type 2 Diabetes: A Narrative Review of the Evidence. Nutrients 2019; 11: pii: E766.
- 8Halford JC, Harrold JA. 5-HT(2C) receptor agonists and the control of appetite. Handb Exp Pharmacol 2012; 349–356.
- 9Bello NT. Update on drug safety evaluation of naltrexone/bupropion for the treatment of obesity. Expert Opin Drug Saf 2019; 18(7): 549–52.
- 10Garvey WT, Ryan DH, Bohannon NJ, Kushner RF, Rueger M, Dvorak RV et al. Weight-loss therapy in type 2 diabetes: effects of phentermine and topiramate extended release. Diabetes Care 2014; 37: 3309–3316.
- 11Knudsen LB, Lau J. The Discovery and Development of Liraglutide and Semaglutide. Frontiers Endocrinol 2019; 10: 155.
- 12Greenway FL, Aronne LJ, Raben A, Astrup A, Apovian CM, Hill JO et al. A Randomized, Double-Blind, Placebo-Controlled Study of Gelesis100: A Novel Nonsystemic Oral Hydrogel for Weight Loss. Obesity (Silver Spring, Md) 2019; 27: 205–216.
- 13Wright LA, Hirsch IB. Non-insulin treatments for Type 1 diabetes: critical appraisal of the available evidence and insight into future directions. Diabet Med 2019; 36: 665–678.
- 14Taylor SI, Blau JE, Rother KI, Beitelshees AL. SGLT2 inhibitors as adjunctive therapy for type 1 diabetes: balancing benefits and risks. Lancet Diabetes Endocrinol 2019; 7: 949–958.
- 15Buse JB, Garg SK, Rosenstock J, Bailey TS, Banks P, Bode BW et al. Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 Study. Diabetes Care 2018; 41: 1970–1980.
- 16Patoulias D, Doumas M, Kotsis V, Stavropoulos K, Imprialos K, Zografou I et al. Liraglutide as adjunct to insulin treatment in patients with type 1 diabetes: A systematic review and meta-analysis. Curr Diabetes Rev 2019; https://doi.org/10.2174/1573399815666190614141918. [Epub ahead of print].
- 17Farooqi IS, Matarese G, Lord GM, Keogh JM, Lawrence E, Agwu C et al. Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J Clin Invest 2002; 110: 1093–1103.
- 18Clement K, Biebermann H, Farooqi IS, Van der Ploeg L, Wolters B, Poitou C et al. MC4R agonism promotes durable weight loss in patients with leptin receptor deficiency. Nat Med 2018; 24: 551–555.
- 19Khorgami Z, Shoar S, Saber AA, Howard CA, Danaei G, Sclabas GM. Outcomes of Bariatric Surgery Versus Medical Management for Type 2 Diabetes Mellitus: a Meta-Analysis of Randomized Controlled Trials. Obes Surg 2019; 29: 964–974.
- 20Sjostrom L, Peltonen M, Jacobson P, Ahlin S, Andersson-Assarsson J, Anveden A et al. Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications. JAMA 2014; 311: 2297–3304.
- 21Yan W, Bai R, Li Y, Xu J, Zhong Z, Xing Y et al. Analysis of Predictors of Type 2 Diabetes Mellitus Remission After Roux-en-Y Gastric Bypass in 101 Chinese Patients. Obes Surg 2019; 29: 1867–1873.
- 22Lee CJ, Florea L, Sears CL, Maruthur N, Potter JJ, Schweitzer M et al. Changes in Gut Microbiome after Bariatric Surgery Versus Medical Weight Loss in a Pilot Randomized Trial. Obes Surg 2019; 29: 3239–3245.
- 23Sheng B, Truong K, Spitler H, Zhang L, Tong X, Chen L. The Long-Term Effects of Bariatric Surgery on Type 2 Diabetes Remission, Microvascular and Macrovascular Complications, and Mortality: a Systematic Review and Meta-Analysis. Obes Surg 2017; 27: 2724–2732.
- 24O'Brien R, Johnson E, Haneuse S, Coleman KJ, O'Connor PJ, Fisher DP et al. Microvascular Outcomes in Patients With Diabetes After Bariatric Surgery Versus Usual Care: A Matched Cohort Study. Ann Intern Med 2018; 169: 300–310.
- 25Fisher DP, Johnson E, Haneuse S, Arterburn D, Coleman KJ, O'Connor PJ et al. Association Between Bariatric Surgery and Macrovascular Disease Outcomes in Patients With Type 2 Diabetes and Severe Obesity. JAMA 2018; 320: 1570–1582.
- 26Aminian A, Zajichek A, Arterburn DE, Wolski KE, Brethauer SA, Schauer PR et al. Association of Metabolic Surgery With Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes and Obesity. JAMA 2019; https://doi.org/10.1001/jama.2019.14231. [Epub ahead of print].
- 27Aghili R, Malek M, Tanha K, Mottaghi A. The Effect of Bariatric Surgery on Peripheral Polyneuropathy: a Systematic Review and Meta-analysis. Obes Surg 2019; 29: 3010–3020.
- 28Casellini CM, Parson HK, Hodges K, Edwards JF, Lieb DC, Wohlgemuth SD et al. Bariatric Surgery Restores Cardiac and Sudomotor Autonomic C-Fiber Dysfunction towards Normal in Obese Subjects with Type 2 Diabetes. PloS One 2016; 11: e0154211.
- 29Xu J, Wu Q, Zhang Y, Pei C. Effect of Bariatric Surgery on Male Sexual Function: A Meta-Analysis and Systematic Review. Sex Med 2019; 7: 270–281.
- 30Pham NH, Bena J, Bhatt DL, Kennedy L, Schauer PR, Kashyap SR. Increased Free Testosterone Levels in Men with Uncontrolled Type 2 Diabetes Five Years After Randomization to Bariatric Surgery. Obes Surg 2018; 28: 277–280.
- 31Ho JH, Adam S, Azmi S, Ferdousi M, Liu Y, Kalteniece A et al. Male sexual dysfunction in obesity: The role of sex hormones and small fibre neuropathy. PloS One 2019; 14: e0221992.
- 32Hussain A. The effect of metabolic surgery on type 1 diabetes: meta-analysis. Arch Endocrinol Metab 2018; 62: 172–178.
- 33Salminen P, Helmio M, Ovaska J, Juuti A, Leivonen M, Peromaa-Haavisto P et al. Effect of Laparoscopic Sleeve Gastrectomy vs Laparoscopic Roux-en-Y Gastric Bypass on Weight Loss at 5 Years Among Patients With Morbid Obesity: The SLEEVEPASS Randomized Clinical Trial. JAMA 2018; 319: 241–254.
- 34Peterli R, Wolnerhanssen BK, Vetter D, Nett P, Gass M, Borbely Y et al. Laparoscopic Sleeve Gastrectomy Versus Roux-Y-Gastric Bypass for Morbid Obesity-3-Year Outcomes of the Prospective Randomized Swiss Multicenter Bypass Or Sleeve Study (SM-BOSS). Ann Surg 2017; 265: 466–473.
- 35Robert M, Espalieu P, Pelascini E, Caiazzo R, Sterkers A, Khamphommala L et al. Efficacy and safety of one anastomosis gastric bypass versus Roux-en-Y gastric bypass for obesity (YOMEGA): a multicentre, randomised, open-label, non-inferiority trial. Lancet (London, England) 2019; 393: 1299–1309.
- 36Murphy R, Clarke MG, Evennett NJ, John Robinson S, Lee Humphreys M, Hammodat H et al. Laparoscopic Sleeve Gastrectomy Versus Banded Roux-en-Y Gastric Bypass for Diabetes and Obesity: a Prospective Randomised Double-Blind Trial. Obes Surg 2018; 28: 293–302.
- 37Vives M, Molina A, Danus M, Rebenaque E, Blanco S, Paris M et al. Analysis of Gastric Physiology After Laparoscopic Sleeve Gastrectomy (LSG) With or Without Antral Preservation in Relation to Metabolic Response: a Randomised Study. Obes Surg 2017; 27: 2836–2844.
- 38Rubino F, Nathan DM, Eckel RH, Schauer PR, Alberti KG, Zimmet PZ et al. Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: a Joint Statement by International Diabetes Organizations. Obes Surg 2017; 27: 2–21.
- 39Miras AD, Perez-Pevida B, Aldhwayan M, Kamocka A, McGlone ER, Al-Najim W et al. Adjunctive liraglutide treatment in patients with persistent or recurrent type 2 diabetes after metabolic surgery (GRAVITAS): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2019; 7: 549–559.
- 40Shah A, Levesque K, Pierini E, Rojas B, Ahlers M, Stano S et al. Effect of sitagliptin on glucose control in type 2 diabetes mellitus after Roux-en-Y gastric bypass surgery. Diabetes Obes Metab 2018; 20: 1018–1023.
- 41Koehestanie P, de Jonge C, Berends FJ, Janssen IM, Bouvy ND, Greve JW. The effect of the endoscopic duodenal-jejunal bypass liner on obesity and type 2 diabetes mellitus, a multicenter randomized controlled trial. Ann Surg 2014; 260: 984–992.
- 42Betzel B, Homan J, Aarts EO, Janssen IMC, de Boer H, Wahab PJ et al. Weight reduction and improvement in diabetes by the duodenal-jejunal bypass liner: a 198 patient cohort study. Surg Endosc 2017; 31: 2881–2891.
- 43Patel N, Mohanaruban A, Ashrafian H, Le Roux C, Byrne J, Mason J et al. EndoBarrier(R): a Safe and Effective Novel Treatment for Obesity and Type 2 Diabetes? Obes Surg 2018; 28: 1980–1989.
- 44van Rijn S, Roebroek YGM, de Jonge C, Greve JWM, Bouvy ND. Effect of the EndoBarrier Device: a 4-Year Follow-up of a Multicenter Randomized Clinical Trial. Obes Surg 2019; 29: 1117–1121.
- 45Glaysher MA, Mohanaruban A, Prechtl CG, Goldstone AP, Miras AD, Lord J et al. A randomised controlled trial of a duodenal-jejunal bypass sleeve device (EndoBarrier) compared with standard medical therapy for the management of obese subjects with type 2 diabetes mellitus. BMJ Open 2017; 7: e018598.
- 46Cohen RV, Oliveira da Costa MV, Charry L, Heins E. Endoscopic gastroplasty to treat medically uncontrolled obesity needs more quality data: A systematic review. Surg Obes Relat Dis 2019; 15: 1219–1224.
- 47Sullivan S, Swain JM, Woodman G, Antonetti M, De La Cruz-Munoz N, Jonnalagadda SS et al. Randomized sham-controlled trial evaluating efficacy and safety of endoscopic gastric plication for primary obesity: The ESSENTIAL trial. Obesity (Silver Spring, Md) 2017; 25: 294–301.
- 488. Obesity Management for the Treatment of Type 2 Diabetes: Standards of Medical Care in Diabetes-2019. Diabetes Care 2019; 42(Suppl. 1): S81–S89.
- 49Inge TH, Laffel LM, Jenkins TM, Marcus MD, Leibel NI, Brandt ML et al. Comparison of Surgical and Medical Therapy for Type 2 Diabetes in Severely Obese Adolescents. JAMA Pediatr 2018; 172: 452–460.
- 50Pratt JSA, Browne A, Browne NT, Bruzoni M, Cohen M, Desai A et al. ASMBS pediatric metabolic and bariatric surgery guidelines, 2018. Surg Obes Relat Dis 2018; 14(7): 882–901.
Citing Literature
